Supp Figure 1 from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
crossref（2023）
摘要
Supplementary Fig 1. (A) PFS in plasma VEGF-C subgroups, (B) OS in plasma Ang-2 subgroups.
查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要